Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
Verrica Pharmaceuticals (NASDAQ: VRCA), a dermatology therapeutics company, announced its participation in the upcoming Jefferies Global Healthcare Conference in New York City. The company's President and CEO, Jayson Rieger, PhD, MBA, will deliver a presentation on Wednesday, June 4, 2025, at 4:20 pm ET.
The event will be accessible via live webcast through the company's website and a dedicated link. A replay will be available for 90 days following the presentation in the Investors/Presentations & Events section of www.verrica.com.
Verrica Pharmaceuticals (NASDAQ: VRCA), azienda specializzata in terapie dermatologiche, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference che si terrà a New York City. Il Presidente e CEO dell'azienda, Jayson Rieger, PhD, MBA, terrà una presentazione il mercoledì 4 giugno 2025 alle 16:20 ET.
L'evento sarà accessibile tramite webcast in diretta sul sito web dell'azienda e tramite un link dedicato. Una registrazione sarà disponibile per 90 giorni dopo la presentazione nella sezione Investitori/Presentazioni & Eventi su www.verrica.com.
Verrica Pharmaceuticals (NASDAQ: VRCA), una compañía de terapias dermatológicas, anunció su participación en la próxima Jefferies Global Healthcare Conference en la ciudad de Nueva York. El presidente y CEO de la empresa, Jayson Rieger, PhD, MBA, ofrecerá una presentación el miércoles 4 de junio de 2025 a las 4:20 pm ET.
El evento será accesible mediante una transmisión en vivo a través del sitio web de la empresa y un enlace dedicado. Una repetición estará disponible durante 90 días después de la presentación en la sección de Inversores/Presentaciones y Eventos en www.verrica.com.
Verrica Pharmaceuticals (NASDAQ: VRCA)는 피부 치료제 전문 기업으로, 곧 뉴욕시에서 열리는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Jayson Rieger 박사(MBA)는 2025년 6월 4일 수요일 오후 4시 20분(동부시간)에 발표를 진행할 예정입니다.
이번 행사는 회사 웹사이트와 전용 링크를 통해 실시간 웹캐스트로 시청할 수 있습니다. 발표 후 90일간 www.verrica.com의 투자자/프레젠테이션 및 이벤트 섹션에서 다시보기 서비스를 제공합니다.
Verrica Pharmaceuticals (NASDAQ : VRCA), une société spécialisée dans les traitements dermatologiques, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference à New York. Le président-directeur général de la société, Jayson Rieger, PhD, MBA, présentera le mercredi 4 juin 2025 à 16h20 ET.
L'événement sera accessible en webcast en direct via le site internet de la société et un lien dédié. Un replay sera disponible pendant 90 jours après la présentation dans la section Investisseurs/Présentations & Événements sur www.verrica.com.
Verrica Pharmaceuticals (NASDAQ: VRCA), ein Unternehmen für dermatologische Therapien, gab seine Teilnahme an der kommenden Jefferies Global Healthcare Conference in New York City bekannt. Der Präsident und CEO des Unternehmens, Jayson Rieger, PhD, MBA, wird am Mittwoch, den 4. Juni 2025, um 16:20 Uhr ET eine Präsentation halten.
Die Veranstaltung wird per Live-Webcast über die Unternehmenswebsite und einen speziellen Link zugänglich sein. Eine Aufzeichnung wird für 90 Tage nach der Präsentation im Bereich Investoren/Präsentationen & Veranstaltungen auf www.verrica.com verfügbar sein.
- None.
- None.
WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City.
Jefferies Global Healthcare Conference, June 3-5, 2025
Event details:
Date: Wednesday, June 4, 2025
Time: 4:20 pm ET
Location: New York, New York
Participants may access a live webcast of the event by clicking the link here.
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
When is Verrica Pharmaceuticals (VRCA) presenting at the Jefferies Global Healthcare Conference 2025?
Who will represent Verrica Pharmaceuticals (VRCA) at the Jefferies Healthcare Conference 2025?
How can investors access Verrica Pharmaceuticals' (VRCA) presentation at the Jefferies Conference?
What is Verrica Pharmaceuticals' (VRCA) main business focus?
